← Back to patent-cliff list
Pacritinib Citrate
Tier C — Watch / tradePacritinib Citrate
S*BIO Pte Ltd
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK2, JAK2 V617F, FLT3, IRAK1, ACVR1, CSF1R
Brand：Epjevy, ENPAXIQ, VONJO
Indications (approved)：Myelofibrosis
Regional status
US
Approved
2022-02-28
EU
Phase III
2013-01-01
China
-
Japan
Phase III
2017-06-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pacritinib Citrate?
Approved indications include: Myelofibrosis.
When does the Pacritinib Citrate patent expire?
No public expiry year is available for Pacritinib Citrate yet; this page updates once verified.
How do I get a quote for Pacritinib Citrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27